

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application Number : TBA Confirmation No.: TBA  
First Named Inventor : INOUE et al.  
Filed : December 13, 2005  
Title : PYRIDINYLPYRAZOLOPYRIMIDINONE DERIVATIVES AS  
PDE 7 INHIBITORS  
TC/Art Unit TBA  
Examiner: TBA  
  
Docket No. : 58778.000005  
Customer No. : 21967

INFORMATION DISCLOSURE STATEMENT

**MAIL STOP PCT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In accordance with 37 C.F.R. §§ 1.97 and 1.98, and in compliance with the duty of disclosure set forth in 37 C.F.R. § 1.56, Applicants are submitting herewith copies of the references other than U.S. patents and U.S. patent publications listed on the attached Form PTO/SB/08A (modified) for consideration and request the documents cited therein be made of record by the U.S. Patent and Trademark Office in the above-captioned application.

Several of the documents listed on the attached Form PTO/SB/08A (modified) were cited by the European Patent Office in the International Search Report, mailed on September 22, 2004, for International Application No. PCT/JP2004/008643. A copy of the International Search Report is enclosed herein.

Consideration of the foregoing plus the prompt return of a copy of the enclosed Form PTO/SB/08A with the Examiner's initials in the left column in accordance with M.P.E.P. § 609 are respectfully requested.

Applicants respectfully point out that the submission of the listed documents in this Information Disclosure Statement is not an admission that they are prior art or that they are

IAP9 Rec'd PCT/PTO 13 DEC 2005

material to patentability of any claims of the application. Also, the submission of this Information Disclosure Statement is not an indication that a search has been made by Applicants.

For the convenience of the Examiner in considering the cited documents, a copy of each of the cited documents other than U.S. patents and U.S. patent publications is enclosed with this communication. In considering the cited documents, it may be noted by the Examiner that certain of the documents may contain markings, underlinings, and/or other notations. These markings, underlinings, and/or other notations are not to be construed as drawing the Examiner's attention either to selected parts or away from other parts of the cited documents. Any such markings were either present on the copies of the cited documents obtained by the associated individuals, or were made thereon during the study of the documents by the associated individuals.


In accordance with 37 C.F.R. § 1.97(b), this Information Disclosure Statement is believed to be submitted prior to issuance of a first Office Action. Therefore, it is respectfully submitted that no fee is required for consideration of this information. However, in the event any fee is deemed necessary, the Commissioner is authorized to charge the undersigned's Deposit Account No. 50-0206:

Respectfully submitted,

HUNTON & WILLIAMS LLP

Dated: December 13, 2005

By:



Robert M. Schulman  
Registration No. 31,196

Alexander H. Spiegler  
Registration No. 56,625

Hunton & Williams LLP  
Intellectual Property Department  
1900 K Street, N.W.  
Suite 1200  
Washington, DC 20006  
(202) 955-1500 (telephone)  
(202) 778-2201 (facsimile)  
RMS/AHS:sac

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

IAPQ Rec'd PCT/PTO 19 DEC 2005

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Application Number	To be assigned
Filing Date	December 13, 2005
First Named Inventor	INOUE et al.
Art Unit	To be assigned
Examiner Name	To be assigned
Attorney Docket Number	58778.000005

Sheet 2 of 4

**FOREIGN PATENT DOCUMENTS**

*Examiner Initial	Cite No.	FOREIGN PATENT DOCUMENT		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	TRANSLATION	
		Country Code Number-Kind Code (if known)					YES	NO
		EP	1176147	01-30-2002	Pfizer Limited, Pfizer Inc.		<input type="checkbox"/>	<input type="checkbox"/>
		EP	1092720	04-18-2001	Pfizer Limited, Pfizer Inc.		<input type="checkbox"/>	<input type="checkbox"/>
		EP	0995750	04-26-2000	Pfizer Limited, Pfizer Inc.		<input type="checkbox"/>	<input type="checkbox"/>
		WO	01/34601	05-17-2001	Merck Patent GmbH		<input type="checkbox"/>	<input type="checkbox"/>
		WO	00/68203	11-16-2000	Takeda Checmical Industries, LTD.		<input type="checkbox"/>	<input type="checkbox"/>
		WO	01/32618	05-10-2001	Merck Patent GmbH		<input type="checkbox"/>	<input type="checkbox"/>
		DE	19950647	04-26-2001	Merck Patent GmbH		<input type="checkbox"/>	<input type="checkbox"/>
		WO	02/088080	11-07-2002	Bristol-Myers Squibb Co.		<input type="checkbox"/>	<input type="checkbox"/>
		WO	02/087513	11-07-2002	Bristol-Myers Squibb Co.		<input type="checkbox"/>	<input type="checkbox"/>
		WO	02/102315	12-27-2002	Bristol-Myers Squibb Co.		<input type="checkbox"/>	<input type="checkbox"/>
		WO	02/074754	09-26-2002	Warner-Lambert Co.		<input type="checkbox"/>	<input type="checkbox"/>
		WO	02/028847	4-11-2002	Warner-Lambert Co.		<input type="checkbox"/>	<input type="checkbox"/>
		WO	01/98274	12-27-2001	Celltech Chiroscience Ltd.		<input type="checkbox"/>	<input type="checkbox"/>
		WO	01/74786	10-11-2001	Darwin Discovery LTD.		<input type="checkbox"/>	<input type="checkbox"/>
		WO	02/40450	05-23-2002	BYK Gulden Lomberg Chemische Fabrik GmbH		<input type="checkbox"/>	<input type="checkbox"/>
		EP	463756	01-02-1992	Pfizer, Inc.		<input type="checkbox"/>	<input type="checkbox"/>
		EP	526004	02-03-1993	Pfizer, Inc.		<input type="checkbox"/>	<input type="checkbox"/>
							<input type="checkbox"/>	<input type="checkbox"/>
							<input type="checkbox"/>	<input type="checkbox"/>

EXAMINER SIGNATURE

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

PTO/SB/08B (08/03) (modified)

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(use as many sheets as necessary)</i>		<b>Application Number</b>	<i>To be assigned</i>
		<b>Filing Date</b>	<b>December 13, 2005</b>
		<b>First Named Inventor</b>	<b>INOUE et al.</b>
		<b>Art Unit</b>	<i>To be assigned</i>
		<b>Examiner Name</b>	<i>To be assigned</i>
<b>Sheet</b>	<b>4 of 4</b>	<b>Attorney Docket Number</b>	<b>58778.000005</b>

**OTHER DOCUMENTS - NON-PATENT LITERATURE DOCUMENTS**

*Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	TRANSLATION	
			YES	NO
		Barnes et al. "Synthesis and Structure-Activity Relationships of Guanine Analogues as Phosphodiesterase 7 (PDE7) Inhibitors." Bioorg. Med. Chem. Lett. (2001), Vol. 11, pgs. 1081-1083.	<input type="checkbox"/>	<input type="checkbox"/>
		Martinez et al. "Benzyl Derivatives of 2,1,3-Benzo- and Benzothieno[3,2-a]thiadiazine 2,2-Dioxides: First Phosphodiesterase 7 Inhibitors." J. Med. Chem. (2000), Vol. 43, pgs. 683-689.	<input type="checkbox"/>	<input type="checkbox"/>
		Castro et al. "CoMFA of benzyl derivatives of 2,1,3-benzo and benzothieno[3,2-a]thiadiazine 2,2-dioxides: clues for the design of phosphodiesterase 7 inhibitors." Eur. J. Med. Chem. (2001), Vol. 36, pgs. 333-338.	<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>

<b>EXAMINER SIGNATURE</b>	<b>DATE CONSIDERED</b>
---------------------------	------------------------

**\*EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.